Dr. Brian Mehling

Dr. Brian Mehling |Clyto Access

Trauma surgeon, USA

Keynote Speaker

Expertise:

Biography: Dr. Brian Mehling, M.D., M.S. is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. Dr. Mehling started his path in medicine through undergraduate study at Harvard University, obtaining Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State university. Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia,  PA, while pursuing a Ph.D. in Chemistry. Dr. Mehling operates his own practice, Mehling Orthopedics, in both West Islip, NY and Hackensack, NJ.

Presentation:

Title: Clinical applications of mesenchymal stem cells

Abstract: BHI Therapeutic Sciences, LLC is a healthcare research and consulting company with focus on high-quality advanced stem cell therapies for regenerative medicine. BHI provides the highest quality care and service available in surgical and medical therapies globally, the most advanced technologies currently available in areas such as stem cell therapy, regenerative medicine, immunocancer therapy, and also provides resources for those who are medically undeserved. BHI Therapeutic Sciences offers a novel method of arthritis therapy using a patient’s own stromal vascular fraction (SVF) cells including mesenchymal stem cells. The therapy is available at Malacky Hospital in Slovakia. Malacky Hospital is staffed with expertly-trained medical professionals and is one of the premiere hospitals in Central Europe. Blue Horizon International Slovakia is licensed by the Ministry of Health of Slovak Republic to provide adipose stem cell treatments for orthopedic joint applications - knees, hips, shoulders, and ankles. Procedures utilise cutting-edge technology and adult stem cells only. In 2015, 73 patients underwent the therapy with own stromal vascular fractioncells. 64 patients have follow-up evaluation results. Affected area includes knees (37 patients), hips (25 patients), hips and knees (2 patients). Follow-up examination results conducted 10 days, 3 and 6 months after treatment have shown significant improvement of clinical conditions relating to pain relief, improved mobility, which was shown also on the follow-up MRI scans of the affected joints. Results from patients’ follow-up examinations and MRI scans showed that stem cell therapy was safe and effective in the improvement of symptoms related to musculoskeletal conditions.   Further close monitoring of subjects, inclusion of more subjects are important to fully characterise the advantages of stem cell therapy of symptoms related to musculoskeletal conditions.

Related Conferences :

Global Forum on Transplantation Research and Technologies